Regencell Bioscience Limited

1 month ago · seekingalpha.com

RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth and a PE of 15.7. The company offers a 4.04% forward dividend yield, supported by an 82-year dividend history and consistent annual payout increases.

2 months ago · marketbeat.com

RGC Resources NASDAQ: RGCO reported fiscal 2026 third-quarter net income of about $550,000, or $0.05 per diluted share, as higher margins supported results despite uneven weather patterns, increased operating expenses and the loss of a large industrial customer.

3 months ago · seekingalpha.com

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.

3 months ago · globenewswire.com

ROANOKE, Va., June 29, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company's common stock. The dividend will be paid on August 3, 2026 to shareholders of record on July 17, 2026. This is the Company's 329th consecutive quarterly cash dividend.

3 months ago · globenewswire.com

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) and certain officers.  The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

3 months ago · prnewswire.com

NEW YORK, June 23, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and certain of its officers.

3 months ago · gurufocus.com

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limit

3 months ago · globenewswire.com

LOS ANGELES, June 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regencell Bioscience Holdings Limited, (“Regencell” or the "Company") (NASDAQ: RGC) investors of a class action on behalf of investors that bought securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell investors have until June 23, 2026 to file a lead plaintiff motion.

3 months ago · prnewswire.com

NEW YORK, June 23, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC). Shareholders who purchased shares of RGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

3 months ago · prnewswire.com

NEW YORK, June 23, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"), of the important June 23, 2026 lead plaintiff deadline. So what: If you purchased Regencell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.